Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Single-Institution Analysis of Factors Associated With Treatment Completion and Survival

被引：0
|
作者：
Bang, A. [1 ]
Malone, S. [1 ]
Leung, E. Y. C. [2 ]
Canil, C. [1 ]
Eapen, L. [1 ]
Morgan, S. C. [1 ]
机构：
[1] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Ottawa Hosp, Ottawa, ON, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.1276
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2633
引用
收藏
页码：E260 / E261
页数：2
相关论文
共 50 条
  • [21] Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
    A. Rodriguez-Vida
    M. D. Torregrosa
    Á. Pinto
    M. Á. Climent
    D. Olmos
    J. Carles
    Clinical and Translational Oncology, 2018, 20 : 679 - 686
  • [22] Radium-223 in metastatic castration resistant prostate cancer
    Vuong, Winston
    Sartor, Oliver
    Pal, Sumanta K.
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 348 - 353
  • [23] Predictors for survival after radium-223 (R223) treatment for castration-resistant metastatic prostate cancer.
    Anderson, Eric
    Wong, William
    Mohammadi, Homan
    Daniels, Thomas Backus
    Tzou, Katherine S.
    Schild, Steven E.
    Keole, Sameer R.
    Choo, Richard
    Bryce, Alan H.
    Thai Huu Ho
    Quevedo, Fernando
    Vora, Sujay A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] RADIUM 223 FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Miranda, Jesus
    Vinal, David
    Pinto, Alvaro
    ARCHIVOS ESPANOLES DE UROLOGIA, 2019, 72 (05): : 500 - 507
  • [25] Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
    Aprile, Carlo
    Persico, Marco G.
    Lodola, Lorenzo
    Buroni, Federica E.
    WORLD JOURNAL OF RADIOLOGY, 2016, 8 (10): : 816 - 818
  • [26] Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome
    Cheng, Sierra
    Arciero, Vanessa
    Goldberg, Hanan
    Tajzler, Camilla
    Manganaro, Aileen
    Kozlowski, Natascha
    Rowbottom, Leigha
    McDonald, Rachel
    Chow, Ronald
    Vasisht, Gaurav
    Shaji, Sharon
    Wong, Emily Chu Lee
    Petrovic, Michele
    Zhang, Liying
    Phillips, Cameron
    Zalewski, Pawel
    Kapoor, Anil
    Fleshner, Neil E.
    Chow, Edward
    Emmenegger, Urban
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9307 - 9319
  • [27] Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
    Anido-Herranz, Urbano
    Fernandez-Calvo, Ovidio
    Ruiz-Banobre, Juan
    Martinez-Breijo, Sara
    Fernandez-Nunez, Natalia
    Nogareda-Seoane, Zulema
    Garrido-Pumar, Miguel
    Casas-Nebra, Javier
    Muniz-Garcia, Gloria
    Portela-Pereira, Paula
    Gomez-Caamano, Antonio
    Perez-Fentes, Daniel Adolfo
    Santome-Couto, Lucia
    Lazaro, Martin
    Molina-Diaz, Aurea
    Medina-Colmenero, Ana
    Vazquez-Estevez, Sergio
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [28] Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
    Peters, Michel L.
    de Meijer, Claudine
    Wyndaele, Dirk
    Noordzij, Walter
    Leliveld-Kors, Annemarie M.
    van den Bosch, Joan
    van den Berg, Pieter H.
    Baka, Agni
    Gaultney, Jennifer G.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (01) : 133 - 143
  • [29] Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging
    Iizuka, Junpei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 16 - 23
  • [30] Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223
    Mukherji, Deborah
    El Dika, Imane
    Temraz, Sally
    Haidar, Mohammed
    Shamseddine, Ali
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 373 - 380
12345